Conference Coverage

CGRP-targeted migraine prevention drugs succeed in phase II


 

FROM THE AAN 2014 ANNUAL MEETING

Drugs that hit CGRP may even help other headache types, Dr. Dodick added.

"There is some evidence that CGRP is also important in other serious headache disorders such as chronic migraine, medication overuse headache, and cluster headache – disorders that are currently very difficult to manage."

The ALD403 study was supported by Alder Biopharmaceuticals. The LY2951742 study was supported by Arteaus Therapeutics in conjunction with Eli Lily. Both Dr. Goadsby and Dr. Dodick have financial relationships with numerous pharmaceutical companies, including receiving research monies, and participating as officers or speakers.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

ACP urges changes to curb prescription drug abuse
MDedge Psychiatry
Drug or sham? Migraineurs responded to placebo 40% of the time
MDedge Psychiatry
FDA: Stop prescribing combo drugs with high-dose acetaminophen
MDedge Psychiatry
Physicians are major source for frequent opioid misusers
MDedge Psychiatry
Group issues recommendations for genetic susceptibility testing for carbamazepine skin reactions
MDedge Psychiatry
Two definitions of Gulf War illness recommended
MDedge Psychiatry
FDA okays first migraine prevention device
MDedge Psychiatry
Sen. Manchin urges withdrawal of Zohydro approval
MDedge Psychiatry
Naloxone autoinjector approved for caregiver use in treating opioid overdoses
MDedge Psychiatry
VIDEO: Practice pearls for treating opiate dependence
MDedge Psychiatry